ライフサイエンスコーパス: ENT1

1 ENT1 is an equilibrative nucleoside transporter that ena

2 via equilibrative nucleoside transporter 1 (ENT1) homologs.

3 the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to accumulation of extracell

4 n of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) i

5 ter, equilibrative nucleoside transporter 1 (ENT1), was associated with the co-occurrence of sleep pr

6 n of equilibrative nucleoside transporter 1 (ENT1).

7 the equilibrative nucleoside transporter 1 (ENT1; also called SLC29a1) is known not to alter its abi

8 with equilibrative nucleoside transporter 1 (ENT1; SLC29A1) are known to be affected by cysteine-modi

9 mber equilibrative nucleoside transporter-1 (ENT1) in the regulation of cardiac adenosine levels.

10 the equilibrative nucleoside transporter-1 (ENT1).

11 uilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2) inhibitory activity albeit less potent th

12 ent with synthetic growth defects of pan1-20 ENT1(EE) cells, overexpressing glutamate-substituted Ent

13 ic growth defects were observed in a pan1-20 ENT1(EE) double mutant, suggesting that Ent1p phosphoryl

14 In addition, ENT1 inhibition or knockdown reduces glutamate transport

15 o-expressed substance P, IB4 or NF, although ENT1 was most highly expressed in the peptidergic popula

16 constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembra

17 specific to RBV, since transport of another ENT1 substrate, cytidine, was unaffected.

18 ith systematic modification and evaluated as ENT1 inhibitors by flow cytometry.

19 ific nucleoside transporter subtypes such as ENT1 is not established.

20 Because P. berghei ENT1 (PbENT1) shares only 60% amino acid sequence identi

21 distribution studies show that mRNA for both ENT1 isoforms are ubiquitously co-expressed in mouse.

22 SLA2 exhibits genetic interactions with both ENT1 and ENT2, and that the clathrin adaptors and Sla2p

23 R2 expression in the striatum was blunted by ENT1 deletion or A2A receptor (A2AR) antagonism.

24 (18)F-FLT is transported into the cell by ENT1 and ENT2, where it is phosphorylated by TK1 and tra

25 ereas chronic ethanol exposure downregulates ENT1.

26 ffinity K(d) of 0.377 +/- 0.098 nM, and each ENT1 cell has 34,000 transporters with a turnover number

27 e equilibrative nucleoside transporter (ENT) ENT1 or the concentrative nucleoside transporter (CNT) C

28 ave previously shown that mice lacking ENT1 (ENT1 KO) have reduced adenosine levels in the striatum a

29 thanol-sensitive adenosine transporter ENT1 (ENT1(-/-)).

30 ast has two redundant genes encoding epsins, ENT1 and ENT2; deleting both genes is lethal.

31 Next, we exposed ENT1 KO and WT mice to constant light (LL) and found fur

32 to identify inhibitors of the P. falciparum ENT1 (PfENT1) that kill P. falciparum parasites in cultu

33 ble-labeling revealed a punctate pattern for ENT1 closely associated, in some instances, with cell bo

34 zation, which confirms an important role for ENT1/SLC29A1 in human bone homeostasis as recently sugge

35 recycling to the plasma membrane and forces ENT1 to the lysosome for degradation.

36 In sensory ganglia, ENT1 was localized to a high proportion of cell bodies o

37 egion in the translocation function of human ENT1.

38 These studies identify ENT1 and adenosine receptors as key to the process of re

39 These findings implicate ENT1 in liver protection from ischemia and reperfusion i

40 pression and circadian locomotor activity in ENT1 KO mice.

41 We examined circadian locomotor activity in ENT1 KO vs WT littermates and found that ENT1 KO mice we

42 amplitude and reduces ethanol consumption in ENT1-null mice.

43 S and promoted excessive ethanol drinking in ENT1(+/+) mice, but not in ENT1(-/-) mice.

44 ay contribute to increased alcohol intake in ENT1 KO mice.

45 found further elevation in ethanol intake in ENT1 KO, but not in WT mice, supporting the notion that

46 hanol drinking in ENT1(+/+) mice, but not in ENT1(-/-) mice.

47 hich may contribute to alcohol preference in ENT1 KO mice.

48 Q, which possesses the equivalent residue in ENT1, gained uridine transport activity.

49 These individuals lacking ENT1 exhibit periarticular and ectopic mineralization, w

50 We have previously shown that mice lacking ENT1 (ENT1 KO) have reduced adenosine levels in the stri

51 peated CRE sites in both genotypes (CRE-lacZ/ENT1(+/+) mice and CRE-lacZ/ENT1(-/-) mice) and the domi

52 otypes (CRE-lacZ/ENT1(+/+) mice and CRE-lacZ/ENT1(-/-) mice) and the dominant-negative form of CREB,

53 Although the mouse ENT1 (mENT1), expressed in Madin-Darby canine kidney cel

54 alysis of genomic DNA corresponding to mouse ENT1 indicates the isoforms can be produced by alternati

55 Electron microscopy analysis of ENT1 expression in lamina II indicated its presence with

56 Inhibition or deletion of ENT1 reduced the expression of type 2 excitatory amino-a

57 the expression and cellular distribution of ENT1 in rat dorsal horn and sensory ganglia.

58 orin 1, downregulated membrane expression of ENT1 and terminated RBV uptake.

59 7-290)) was used to reveal the expression of ENT1 protein in tissue homogenates of either adult rat d

60 FLI1 inhibitors suppressed the expression of ENT1, ENT2, and TK1 and thus decreased (18)F-FLT PET act

61 cysteine residues in the C-terminal half of ENT1, particularly one or both of those in the fifth int

62 s, we observed higher expressional levels of ENT1 than ENT2, in conjunction with repression of ENT1 a

63 es demonstrated time-dependent repression of ENT1 and ENT2 transcript and protein levels during ALI.

64 than ENT2, in conjunction with repression of ENT1 and ENT2 transcript and protein levels following wa

65 The functional significance of ENT1 expression with regard to the homeostatic regulatio

66 lization was also reduced in the striatum of ENT1 null mice.

67 action of ticagrelor, inhibition of platelet ENT1 and inverse agonism at the P2Y12R that contribute t

68 s similar in potency to the prototype potent ENT1 inhibitor NBMPR (0.43 nM).

69 (3-MA), and bafilomycin A1 (BafA1) prevented ENT1 degradation and enhanced RBV antiviral activity.

70 of the clathrin heavy chain by HCV prevents ENT1 recycling to the plasma membrane and forces ENT1 to

71 tivity albeit less potent than the prototype ENT1 inhibitor nitrobenzylmercaptopurine riboside (NBMPR

72 Sequence alignment of hENT1, mENT1, and rat ENT1 (rENT1) showed that the PEXN motif of hENT1 was sub

73 ponds to the previously cloned human and rat ENT1 proteins at Ser-254.

74 istant cell lines may compensate for reduced ENT1-mediated nucleoside uptake by increasing the activi

75 his study, immunoblot analysis with specific ENT1 antibodies (anti-rENT1(227-290) or anti-hENT1(227-2

76 in ENT1 KO vs WT littermates and found that ENT1 KO mice were both active earlier and hyperactive co

77 Our results indicate that ENT1 antagonists augment oHSV replication in tumor cells

78 Our results indicate that ENT1 has a physiological role in ethanol-mediated behavi

79 Here we report that ENT1-null mice show reduced hypnotic and ataxic response

80 ne reduced ethanol drinking, suggesting that ENT1-mediated downregulation of EAAT2 and AQP4 expressio

81 )-mediated enhancement of the binding of the ENT1 inhibitor nitrobenzylmercaptopurine riboside (NBMPR

82 ignificantly enhanced in the presence of the ENT1 nucleoside transporter inhibitors dipyridamole and

83 developed through reduced RBV uptake via the ENT1 nucleoside transporter and antiviral efficacy was r

84 [(3)H]NBMPR binds to ENT1 cells with a high affinity K(d) of 0.377 +/- 0.098

85 However, in contrast to ENT1 and ENT2, the endogenous and green fluorescent prot

86 e that RBV uptake is restricted primarily to ENT1 in the cell lines examined.

87 king ethanol-sensitive adenosine transporter ENT1 (ENT1(-/-)).

88 d by inhibition of the adenosine transporter ENT1 (type 1 equilibrative nucleoside transporter), whic

89 sitive, equilibrative nucleoside transporter ENT1 and thus was designated ENT2.

90 tion between SLC29A1 (nucleoside transporter ENT1) expression and potency of nucleoside analogues, az

91 type 1 equilibrative nucleoside transporter (ENT1), drink more ethanol compared with wild-type mice a

92 sitive equilibrative nucleoside transporter (ENT1), incubation with SB203580 or SB203580-iodo elimina

93 type 1 equilibrative nucleoside transporter (ENT1), whereas chronic ethanol exposure downregulates EN

94 sitive equilibrative nucleoside transporter (ENT1).

95 ed expression of the nucleoside transporters ENT1 and CNT1.

96 Unlike ENT1-3, PMAT mainly functions as a polyspecific organic

97 s and vascular endothelial cells but, unlike ENT1, is virtually absent from the sinoatrial and atriov

98 It is not known, however, whether ENT1 is important for ethanol intoxication or consumptio

99 However, it is unknown whether ENT1 deletion disrupts circadian rhythms, which may cont

100 Immunoperoxidase labeling with ENT1 antibodies produced specific staining in dorsal hor